Annual Report

Overview

The report presents Genovate's 2023 consolidated operating revenue of NT$528,512 thousand and a year-end Group workforce of 199 employees. It outlines active pharmaceutical R&D, including completed PMR clinical batch production and pharmacokinetic trials and ongoing NF02 epilepsy enrollment. Sustainability disclosures are mainly governance and environmental compliance updates: the Board approved a greenhouse-gas inventory and assurance schedule, while climate targets and the transformation plan remain under development. The report also states that no Sustainability Report was created.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2023
Period: 1 January 2023 – 31 December 2023
Publication date: 8 May 2024
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services